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SELECTION OF THE MONTH 
Urgent need to increase awareness and screening programs for HCV infection  
Reliable data about the population-based prevalence of hepatitis C virus (HCV)-
induced cirrhosis are unavailable for most countries. Udompap et al. addressed this 
question by determining the cirrhosis prevalence using the National Health and 
Nutrition Examination Survey (NHANES), which contains a population generalizable to 
the entire United States households. The authors also raised the important question of 
whether awareness of the infection impacts cirrhosis prevalence. While the overall 
prevalence of HCV infection has decreased over time from 1.5% in 1988-94 (Era 1), to 
1.2% in 1999-2006 (Era 2), and then to 1.0 in 2007-12 (Era 3), the proportion of HCV 
patients with cirrhosis has more than doubled during the study period reaching 17% in 
the latest era. Most importantly, cirrhosis prevalence in patients unaware of their 
infection was as high as in those with established HCV diagnosis. The study 
emphasizes the need for implementing HCV awareness and screening programs for 
primary prevention of cirrhosis and its complication. 
 
 
LIVER INFLAMMATION 
IL-23/IL-17 axis makes liver immunopathology, biliary epithelium surveillance by 
Mucosal-Associated Invariant T (MAIT) cells  
Excessive type 1 immune responses, for example those involving the interleukin (IL)-
23/IL-17 axis, contribute to immunopathology in the context of auto-immune diseases. 
Noll et al. now show that the IL-23/IL-17 axis plays a crucial role in the 
immunopathology of hepatic amebiasis. They also find that CD11b+Ly6Clow 
monocytes may contribute to liver repair via the secretion of IL-13 (a cytokine of the 
type 2 immunity). These findings suggest that stimulation of IL-13 signaling may 
improve liver damage caused by the engagement of the IL-23/IL-17 axis.  
Mucosal-Associated Invariant T (MAIT) cells are innate-like T cells characterized by 
the invariant TCR-chain, Vα7.2-Jα33, and are restricted by the major histocompatibility 
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complex class I-related gene protein (encoded by MR1), which is an antigen-
presenting molecule specialized in presenting microbial vitamin B metabolites. MAIT 
cells play a crucial role in antibacterial immunity of different mucosa but their role in 
the biliary epithelium defense is unknown. Here Jeffery et al. show evidence of an 
immune surveillance effector response for intra-hepatic MAIT cells toward 
biliary epithelial cells in the human liver. MAIT cell usage may be a novel approach 
in the treatment of biliary diseases. 
 
LIVER REGENERATION 
A matter of TNF and TNF receptors super-families 
Tumor necrosis factor (TNF) receptor (TNFR) superfamily member 3 (also known as 
lymphotoxin B receptor) which is encoded by Ltbr (alias Tnfrsf3) is known to be 
involved in liver regeneration in response to injury. The receptor binds different 
members of the TNF ligand superfamily, including lymphotoxin-alpha and –beta, and 
tumor necrosis factor ligand superfamily member 14 (also known as Light). Sorg et al., 
using a model of liver regeneration in genetically modified mice reveal that 
lymphotoxin B receptor is essential for effective liver regeneration and 
cooperates with TNFR superfamily member 1A (also known as p55, and encoded 
by Tnfrsf1a) in this process. p55 receptor recognizes lymphotoxin-alpha and the 
soluble form of TNFα. Together these findings suggest that inhibition of TNF signaling 
may be harmful in the context of liver regeneration 
 
HEPATOCELLULAR CARCINOMA (HCC) 
Effect of salt-inducible kinase 1 (SIK1) silencing, diagnostic criteria for HCC ≤3 
cm, a trial of sorafenib plus DEB-TACE 
SIK1 encodes the serine/threonine-protein kinase SIK1 which is known to be involved 
in various processes such as cell cycle regulation, gluconeogenesis and lipogenesis 
regulation, muscle growth and differentiation and tumor suppression. However, little is 
known about the role of SIK1 function in HCC. Qu et al. show in this issue of the Journal 
that SIK1 silencing promotes HCC progression and WNT/β-catenin pathway 
activation, suggesting new diagnostic and therapeutic approaches in liver 
cancer.  
Current diagnostic imaging criteria for (HCC) are dedicated to imaging with nonspecific 
extracellular contrast agents. Choi et al. investigated diagnostic criteria for HCC ≤3 cm 
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on magnetic resonance imaging (MRI) with a hepatocyte-specific contrast agent 
through an inception cohort study. They report two interesting findings. First, EASL 
criteria exhibit the best diagnostic performance for HCC ≤3 cm on hepatocyte-
specific contrast-enhanced MRI. A newly identified criterion (arterial-phase 
hyper-intensity and hepatobiliary phase hypo-intensity) may increase the 
diagnostic sensitivity of small (≤2 cm) HCC. 
Transarterial chemoembolization with doxorubicin-eluting beads (DEB-TACE) is 
effective in patients with BCLC stage B hepatocellular carcinoma (HCC). Sorafenib 
enhances overall survival and time to tumor progression in patients with advanced 
HCC. Lencioni et al. report the results of an exploratory phase II trial tested the efficacy 
and safety of sorafenib plus DEB-TACE in patients with intermediate-stage HCC. They 
show the technical feasibility of sorafenib plus DEB-TACE, but find no advantage 
in terms of outcome in using this combination therapy compared to DEB-TACE 
alone. 
 
NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) 
Hepatic lipidomic analysis in patients with NASH 
Recent data have identified de novo ceramide synthesis as important mediators of 
hepatic insulin resistance (IR), which participates in NASH progression. In this issue, 
Luukkonen et al. determined which bioactive lipids co-segregate with IR in the human 
liver, and its relationship with PNPLA3 genotypes. By performing liver lipidome 
analysis in patients with and without IR and different PNPLA3 genotypes, they 
demonstrated that steatosis and NASH prevalence were similarly increased in patients 
with IR and PNPLA3148MM/MI at rs738409. The liver in patients with IR had increased 
triacylglycerols as well as markers of de novo ceramide synthesis. In contrast, livers 
from patients with PNPLA3148MM/MI have increased polyunsaturated triacylglycerols 
while other lipids were unchanged. This study suggests the composition liver fat in 
NASH depends on the PNPLA3 genotype. 
 
HEPATITIS C VIRUS (HCV) INFECTION 
Increasing prevalence of HCV-induced cirrhosis in the United States, risk of HCV 
reinfection in injecting drug users – how sustained is sustained response? 
Current guidelines support that HCV-infected people who inject drugs (PWID) are a 
high priority population for anti-viral treatment due to the potential HCV transmission 
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prevention benefit. Nevertheless, access to anti-viral treatment is limited in this patient 
population because of, amongst others, the potential risk of HCV reinfection. However, 
solid follow-up data on the true incidence of chronic reinfection are sparse in this 
setting. Midgard et al. have now showed in a 7 year follow-up study, that the rate of 
persistent HCV reinfection among 94 Norwegian patients with a history of intravenous 
drug use prior to treatment was 11% (incidence 1.7/100 person-years). Reinfection 
only occurred among those who had relapsed to intravenous drug use 
(incidence 4.9/100 person-years), and the relapse to intravenous drug use was the 
only baseline factor associated with reinfection. The study proves the need for 
systematically addressing HCV reinfection risk in PWID and that preventing 
intravenous drug relapse remains the main preventive strategy in a field moving rapidly 
forward. 
 
HEPATITIS B VIRUS (HBV) INFECTION 
“Liver directed” peg-interferon lambda in chronic HBV infection 
Peg-interferon lambda-1a is a polyethylene glycol chain conjugated recombinant 
human Type-III interferon with documented activity against HBV and hepatitis C virus 
(HCV) in vitro. Whereas interferon-alpha receptors are expressed by many cell types, 
lambda receptor expression is more restricted to epithelial cells, hepatocytes and 
plasmacytoid dendritic cells, raising hope that a more liver-targeted interferon 
response induced by lambda interferon may lead to a higher anti-viral efficacy and 
better tolerability as compared to alpha interferons. In a proof-of-concept phase 2b 
study (LIRA-B), Chan et al. evaluated the efficacy and safety of peg-interferon lambda 
vs. peg-interferon alfa-2a monotherapy over 48 weeks in HBeAg-positive chronic HBV 
infection. The major finding from this study was, however, that peg-interferon lambda 
did not meet the criteria for noninferiority to peg-interferon alfa-2a for the 
primary efficacy endpoint of HBeAg seroconversion at week 24 post-treatment 
follow-up (14% vs. 30%), although on-treatment HBV-DNA and HBsAg suppression 
was more pronounced in the peg-interferon lambda treated patients. Due to these 
findings the further development of peg-interferon lambda in chronic hepatitis B was 
stopped.  
 
HEPATITIS E VIRUS (HEV) INFECTION 
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A mouse model for hepatitis E virus infection  
With approximately 20 million new infections per year, HEV is a leading cause of acute 
hepatitis worldwide and may cause numerous extrahepatic manifestations but also 
chronic liver disease in immunocompromised patients. Models to study the molecular 
biology of HEV infection in vivo, and thus the possibility to find new treatment options, 
are still limited to non-human primates and other mammals, and none of these models 
can mimic chronic HEV infections. In this issue of the Journal, Allweiss et al. described 
the first mouse model of HEV infection by employing a human liver chimeric 
mouse (uPA/SCID/beige mice) in which HEV infection and spreading could be 
monitored in blood, liver and other types of tissue down to the single cell level. The 
new in vivo model will be of significant importance in order to study the pathogenicity 
of different HEV strains, innate immunity as well as potential antiviral agents including 
vaccine-induced neutralizing antibodies. 
 
CIRRHOSIS 
Modulation of TLR7/8 restores bactericidal activity of neutrophils, obeticholic 
acid (OCA) restores intestinal permeability, and the disturbances in the 
metabolome predicts mortality in acutely decompensated cirrhosis patients. 
Alterations in liver function, liver injury, bacterial translocation and immune dysfunction 
are inter-related phenomenon in cirrhotic patients. Three excellent papers in the 
current issues of the Journal address these pointing also to potential therapeutic 
strategies.  
In very novel and exciting studies, Boussif et al. define the possible mechanisms of 
why neutrophils from patients with cirrhosis have reduced bactericidal activity. They 
show that the release of neutrophilic myeloperoxidase, which is a key enzyme involved 
in bacterial killing is impaired in cirrhosis. They show that the Akt/MAP kinase 
pathway may be involved in this and the killing function of the cells can be 
restored using a TLR7/8 agonist, providing a potential novel strategy to reduce 
infection rates in cirrhosis patients.  
Ubeda et al. show that the FXR agonist, OCA, when administered to cirrhotic rats 
with ascites significantly reduced the severity of bacterial translocation through 
many associated mechanisms including restoration of the gut tight junctions. 
As a result, the animals had improved liver function and severity of fibrosis, suggesting 
that OCA approach may be useful in preventing the complications of cirrhosis. 
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McPhail and Shawcross et al. performed an extremely novel and extensive study 
focusing on describing the metabolome of patients with acute decompensation of 
cirrhosis. Their data suggest that the alteration in the metabolome defines the 
prognosis of these patients and provides a potentially important biomarker. Of 
course, better understanding of the specific alterations may well provide novel 
therapeutic targets. 
 
LIVER FAILURE AND GROWTH 
Hepatocyte Transplantation in Acute Liver Failure 
The treatment of acute liver failure remains an unmet need. Hepatocyte transplantation 
is an attractive strategy that may allow time for hepatic regeneration while liver function 
is maintained with transplantation of hepatocytes. However, the results of hepatocyte 
transplantation remain poor mainly because of issues related to engraftment of the 
transplanted hepatocytes. Nagamoto et al. address this issue of hepatocyte 
engraftment using a novel cell sheet engineering technology for experimental 
hepatocyte transplantation. The human iPS-HLC sheets were attached onto the liver 
surfaces of mice with liver injury. This strategy was significantly more successful than 
conventional method in reducing the severity of liver injury indicating a potential future 
solution. 
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